长春瑞滨单药周疗方案治疗既往应用过蒽环类和紫杉类药物的晚期乳腺癌临床观察  

Efficacy and safety of vinorelbine in the treatment of metastatic breast cancer patients pretreated with anthracyclines and taxanes

作　　者：韩颖[1] 李青[1] 徐兵河[1] 袁芃[1] 王佳玉[1] 

机构地区：[1]中国医学科学院 北京协和医学院 肿瘤医院内科,北京100021

出　　处：《癌症进展》2012年第3期275-279,共5页Oncology Progress

摘　　要：目的观察长春瑞滨(NVB)单药治疗对既往应用过蒽环类和/或紫杉类药物的转移性乳腺癌的疗效和安全性。方法我院从2008年1月至2011年7月共有31例既往应用过蒽环类和/或紫杉类药物的转移性乳腺癌患者接受了NVB单药周疗方案治疗。结果全组化疗共113个周期,中位化疗周期数为4个(2～6个周期)。完全缓解(CR)1例(3%),部分缓解(PR)7例(22%),稳定(SD)4例(13%),进展(PD)19例(61%),总有效率(RR=CR+PR)为26%,临床获益率(CR+PR+SD>6个月)为32%,中位疾病进展时间(TTP)4.0个月,中位生存期为13个月。主要不良反应为骨髓抑制及胃肠道反应,无化疗相关死亡病例。结论长春瑞滨单药治疗既往应用过蒽环类和/或紫杉类药物的转移性乳腺癌有一定疗效,且耐受性好。Objective To evaluate the efficacy and safety of vinorelbine （NVB） monotherapy in the treatment of me- tastatic breast cancer patients pretreated with anthracyclines and taxanes. Methods From January 2008 to July 2011,31 patients who had already received anthraeycline and taxane were treated with NVB monotherapy, vinorelbine （25 mg/m^2 intravenous infusion, day 1 , 8, 15） was administered to eligible MBC patients previously treated with anthracyclines and taxanes in every 4 weeks for up to 6 cycles, until disease progression occurred or unacceptable toxicity developed. Results A total of 113 cycles were given （median 4 cycles; range 2 -6）. There was 1 case of complete response （CR） （3%）, 7 cases of partial response （PR） （22%）, 4 cases of stable disease （SD） （13%）, as well as 19 cases of disease pro- gression （PD） （61%）, and the overall response rate （ RR = CR ＋ PR） was 26% ; clinical benefit rate （ CR ＋ PR ＋ SD 〉6 months） was 32%. The median time to disease progression （TTP） was 4. 0 months （ range 1 - 18）. The median survival time was 13 months. The most common chemotherapy-related adverse events were myelosuppression with 68% being grade Ⅲ and Ⅳ neutropenia and gastrointestinal reactions. Non-hematologic toxicity was modest and recoverable on discontinua- tion of therapy. Conclusion NVB is active in the treatment of metastatic breast cancer with tolerable toxicity, and may be an effective salvage chemotherapy regimen.

关 键 词：晚期乳腺癌 长春瑞滨 疗效 安全性 

分 类 号：R730.53[医药卫生—肿瘤] R737.9[医药卫生—临床医学]